A biopharmaceutical company focused on developing treatments for central nervous system disorders, including depression and other brain health conditions. Its portfolio includes Zulresso for postpartum depression and drug candidates such as zuranolone developed in partnership with Biogen. Investors ...
1 member of Congress has disclosed 1 trade in Sage Therapeutics Inc (SAGE), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-06-02 | Neal Patrick Dunn | buy | $1K – $15K |